ARCANGELO (itAlian pRospective Study on CANGrELOr)

Study Identifier:
DFIDM-1801
ClinicalTrials.gov Identifier:
NCT04471870
EudraCT Identifier:
N/A
Study Contact Information:
N/A
Study Complete

Study Details

Medical Condition
  • Thrombosis
Study Drug
    Date
    Oct 2020 - Jan 2022
    Phase 1
    Phase 2
    Phase 3
    Phase 4
    N/A
    Patient Requirements
    Sex: Female & Male
    Age: 18+ years
    Requirements Information
    Healthy Volunteers
    No

    Protocol Summary

    The Sponsor implemented a post-authorisation safety study (PASS), category 3, focused in Acute Coronary Syndrome, in order to collect information about the safety of cangrelor in the real clinical practice, evaluating the safety of the transition to all the oral P2Y12 inhibitors (cangrelor, ticagrelor and prasugrel).

    Study Locations

    Location
    Status
    Location
    A.O.U. Riuniti
    Ancona, Italy
    Status
    N/A
    Location
    Ospedale San Donato
    Arezzo, Italy
    Status
    N/A
    Location
    A.O.U. Consorziale Policlinico
    Bari, Italy
    Status
    N/A
    Location
    Ospedale San Bassiano
    Bassano del Grappa, Italy
    Status
    N/A
    Location
    Azienda Ospedaliera San Pio
    Benevento, Italy
    Status
    N/A
    Location
    Ospedale Maggiore
    Bologna, Italy
    Status
    N/A